Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038620 · ClinicalTrials.gov registry record · Phase 4
Impact of Liraglutide 3.0 on Body Fat Distribution
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 235
- Enrollment target
NCT03038620 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 235 participants.
The verdict
NCT03038620, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 235 participants
- Enrollment target
Study Summary
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.
Interventions
- DRUG Placebo
- DRUG Liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-10-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038620
The ClinicalTrials.gov registry entry for NCT03038620 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03038620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03038620 about?
NCT03038620 is a clinical study titled "Impact of Liraglutide 3.0 on Body Fat Distribution". This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.
What is the current status of trial NCT03038620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 235 participants. The study started on 2017-01. Estimated completion is 2020-10-13.
What interventions are being tested in trial NCT03038620?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG).
Who is sponsoring clinical trial NCT03038620?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.